Sana Biotechnology Inc (SANA)

Definitely adds to their legitimacy for me. Going to be a long road though but at least they have a great partner and potential for additional funds

SANA now linked with Mayo, both financially and for development. Couldn't have a better partner.
https://www.tipranks.com/news/company-announcements/sana-biotechnology-secures-strategic-equity-investment-from-mayo

SANA..............................https://stockcharts.com/sc3/ui/?s=SANA&p=w&b=5&g=0&id=p86431144783

SANA..................................a/h

It is interesting technology. Really hope they can get some more people enrolled , and we can get a better idea

It is amazing that this transplant has been working for a year now using unmatched islet cells and NO immune suppression. Admittedly, P-1 has not finished recruiting, but when they can report survivorship of more than one patient, this will explode.

SANA news from 2 weeks ago:
Sana Biotechnology, Inc. (the “Company” or “Sana”) intends to discuss an updated corporate presentation (the “Corporate Presentation”) at the 44th Annual J.P. Morgan
Healthcare Conference on January 14, 2026. A copy of the Corporate Presentation is furnished as Exhibit 99.1 to this Current Report
Company’s programs and platforms, including the following:
• At 12 months post-transplantation into a patient with type 1 diabetes who received no immunosuppression, UP421, a primary pancreatic islet cell therapy
engineered with Sana’s hypoimmune platform (“HIP”) technology, continued to survive, evade immune detection, and function.
• Sana remains on track to file an investigational new drug application (“IND”) and begin a Phase 1 trial for SC451, a HIP-modified, induced pluripotent stem cell
(“iPSC”)-derived pancreatic islet cell therapy, as early as this year.
• Sana announced its goal of generating initial human data as early as this year for SG293, an in vivo CD19-directed CAR T cell therapy.

error

Healthy lifestyle will help type 2 DM, but without insulin and type 1, you will die at a young age. Study human physiology. 

Eating balanced meals (counting carbs), exercising regularly, managing stress, getting enough sleep will help anyone with type 1 diabetes.

Too many BioScams are milking the market.

Exactly. Just because most of these are longshots doesn't mean they are scams. Just don't invest more than one can afford to lose is what I say.

If you had type 1 diabetes, you would care. 

Who cares, they just sell shares for their research.

The system allows that, and they milk as much as they can.

Potential shareholders need to be prudent. Trading, not investing, imo.

Bioscams don't get their work published in peer reviewed journals. 

Another BioScam in the making.

Great info. Thanks. 

Additional upcoming data from early clinical trials for SC451, a stem-cell derived therapy for type 1 diabetes, which is in preclinical development but targeting future clinical readouts.

upcoming clinical data readouts that could impact SANA's (Sana Biotechnology, Inc.) https://www.perplexity.ai/finance/SANA price targets include
Data from the Phase 1 GLEAM trial evaluating SC291, a CD19-directed allogeneic CAR T cell therapy for autoimmune diseases, which Sana expects to share in 2025

 analyst rating of "Strong Buy" from multiple firms, with 11 analysts providing price targets as of late October 2025. The average price target is around $8.70, with the highest target at $15.00 and the lowest at $5.00. The most recent analyst ratings were issued by Citizens, Wedbush, and Morgan Stanley, with targets ranging from $5.00 to $8.00 and $12.00.?

, a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in December. The presentations will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.The webcasts will be accessible on the Investor Relations page of Sana’s website at https://www.globenewswire.com/Tracker?data=j1CZt8aJ3vRIzQKEKkKsvwyGOhmoySrB6li90vptNVrR4yd0q6Gg8zFx78pqHwU5adT3eFQ2yRBfXg7ioNgxNg==. A replay of each presentation will be available at the same location for 30 days following the conference.
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. For more information about Sana Biotechnology, please

$3.79

EMJ Capital President Eric Jackson on Wednesday expressed optimism about Sana Biotechnology (SANA) stock, saying it could become “the next 100-bagger platform.”

SANA shares traded 35% higher at the time of writing.

Jackson took to the social media platform X, opining that SANA stock would eventually explode, and highlighted the company’s various achievements, including its work in type 1 diabetes treatment. In January, Sana said that following a transplant of an allogeneic primary islet cell therapy into a patient with type 1 diabetes, they started producing insulin. The therapy was engineered with Sana’s hypoimmune (HIP) technology, enabling the transplantation without the need for immunosuppression.

Right. I mean it may not work , but it does have monster potential. Hope it isn't too good to be true

Also, the capability of removing the autoimmune factor opens up multiple other applications. 

Thanks. It's certainly an interesting speculative risk/reward stock

A Seeking Alpha analyist called it a hundred bagger. 

Any idea why the move?

Blind squirrel....
9/23/25 09:37:06 BOT +5 SANA 100 17 OCT 25 5 CALL .05 -3.25 -5.00 36,842.73

Yes, I was aware of that. 

Singular Keyword: Patient

Thx

Reread yesterday's PR, 2nd paragraph.

Ok. What phase are we? On the Web site said Ph 1???

Wrong about P-1 testing. See today's PR regarding the NEJ publication.
Sana Biotechnology Announces Publication in New England Journal of Medicine of Groundbreaking Clinical Data from Transplantation Without Immunosuppression of Hypoimmune-Modified, Insulin-Producing Islet Cells in Patient with Type 1 Diabetes •

Thanks.

As far as I know, they are mid-way through P-1. Should finish near the end of the year. If results are as good as the 6 month result, this will take quite a big jump. Plus, it's potential for many other medical uses is staggering.

Hey folks- I found this stock thru my phone advertisement. I don't know anything about this company. I am reading the news they are working on drugs that treats Diabetic I disease, CEO said they got very good results in 6 months period. what kind of trial they are running and when do they expect the results to be published. Tia

37 million short cover to go! Weeeee!

When is the purpose of your posts?by the way, I was mistaken in my prior post. Sana is half way through p-1.

SANA under 6

SANA under 5

Hard to believe this company appears to have the cure for type 1 diabetes and it is just above $4.  Shares are more than 80% owned by funds. Retail buyers haven't realized the potential here, althougt it will be a 2+ year hold. Waiting for the p1 announcement. 

Sana under 4.00

SANA under $3

Steve Harr just presented at Jefferies Global Healthcare Conference on June 4 2025. Basically, the presentation asserted that the company's efforts are bearing fruit according to expectation. He clearly acknowledges that additional funding will be necessary but that has been no secret and is typical of biotech startups. The most interesting items were that Sana (1) will be presenting 6 months results on its SC451 project outcomes on June 23 and (2) expects to have a major journal article published around these results before long. If the six month results are in line with the already published 4,8, and 12 week results, this could be significant. All and all, I was impressed by Harr's command of the facts. For the most part he was able to make the science clear and understandable although he seemed a little blurry when talking about the CAR process. All and all I was impressed by the presentation. It came off as long on fact and short on hype. Sana is a speculation, no doubt. As such, it could go to zero, it could also do quite well.

SANA under $2

SANA, under $2

Lot's of trading voodoo here. Million dollar exchanges not budging the price. Hmmm

Chief Scientist very confident...

already looking good!
Love SANA - looks like t1d CURE - believe it will become a cult stock soon. Right now the naysayers are asking why children wouldnt want to live with needles...
stock should be 6$ even with financing overhang